Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...
BioNTech and its new partner Bristol Myers Squibb have trotted out the first global data for their PD-L1xVEGF bispecific in small cell lung cancer, results BioNTech’s chief medical officer, Özlem ...
The results of a preclinical study have identified a biological mechanism that explains why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. The study, ...
As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes how far the fanfare will spread. It’s more than just existing PD-1/L1 players ...
Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. But with promising early results from a phase 3 study in certain patients, the ...
Akeso is on a winning streak. Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for its PD-1 inhibitor penpulimab co-developed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback